Trial
NCT00766142
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Institut Bergonié
Collaborators
Assistance Publique - Hôpitaux de Paris; Centre Alexis Vautrin, Nancy; Centre Leon Berard; Institut Cancerologie de l'Ouest; Hôpital Haut-Lévêque; Clinique Médicale de Francheville
Condition
Colorectal Cancer
Intervention
cetuximab
Why stopped
In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-29